Oppenheimer analyst Jeff Jones downgraded Pliant Therapeutics (PLRX) to Perform from Outperform without a price target after the company announced a voluntary pause to the enrollment, and dosing, of its Phase 2b BEACON trial based on the recommendation of the Data and Safety Monitoring Board. The firm steps to the sidelines, awaiting further clarity on the DSMB’s reason for recommending the pause, and the path forward for Pliant’s key asset bexotegrast.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLRX:
- Pliant Therapeutics downgraded to Hold from Buy at Canaccord
- Maintaining a Buy Rating on Pliant Therapeutics Despite Bexotegrast Trial Pause and Market Overreaction
- Pliant Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
- Pliant Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Pliant Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo